Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
361-02-003 ISMRM Abstract

MRI-based Habitat radiomics analysis for Predicting Clinically Significant Prostate Cancer: a retrospective dual-center study

Primary: Analysis Methods - Radiomics
Secondary: Body - Prostate
361-02-003 · Prostate: Clinical Applications, AI, and Post-Processing · Monday, 11 May, 9:15 AM–10:10 AM · Digital Posters Row B
Keywords: Radiomics Magnetic resonance imaging Clinically significant prostate cancer Habitat analysis
Accepted
Zefei Chen 1,2, Yongzhou Xu3, Yinquan Ye1,2, Limin Liang1,2
1The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, China
2Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
3Clinical and Technical Support, Philips Healthcare (Guangzhou), Guangzhou, China
Presenting Author: Zefei Chen

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024, 74(3):229-263.
2. Matoso A, Epstein JI: Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology 2019, 74(1):135-145.
3. Raja J, Ramachandran N, Munneke G, Patel U: Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol 2006, 61(2):142-153.
4. Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A: Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol 2015, 68(6):1045-1053.
5. Turkbey B, Purysko AS: PI-RADS: Where Next? Radiology 2023, 307(5):e223128.
6. Huang C, Cai ZQ, Qiu F, Pu JX, Xi QL, Wei XD, Wang XM, Zhao XJ, Guo LC, Hou JQ et al: New model of PIRADS and adjusted prostatespecific antigen density of peripheral zone improves the detection rate of initial prostate biopsy: a diagnostic study. Asian J Androl 2023, 25(1):126-131.
7. Li J, Wang K, Li S, Wu P, Wang X, He Y, Tang W: Clinical study of multifactorial diagnosis in prostate biopsy. Prostate 2023, 83(15):1494-1503.
8. Gillies RJ, Balagurunathan Y: Perfusion MR Imaging of Breast Cancer: Insights Using "Habitat Imaging". Radiology 2018, 288(1):36-37.
9. Sala E, Mema E, Himoto Y, Veeraraghavan H, Brenton JD, Snyder A, Weigelt B, Vargas HA: Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol 2017, 72(1):3-10.
10. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA: The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016, 40(2):244-252.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/361-02-003